Chalcone analogues as potential medicines of pathogenetic therapy of alzheimer's disease: in vitro screening
- 作者: Pozdnyakov D.I.1, Vikhor A.A.1, Rukovitsina V.M.1, Oganesyan E.T.1, Pleten A.P.2, Prokopov A.A.2, Tatarenko-Kozmina T.Y.2
-
隶属关系:
- Pyatigorsk Medical and Pharmaceutical Institute
- Moscow State Medical and Dental University named after A.I. Evdokimov of the Ministry of Health of the Russia
- 期: 卷 27, 编号 2 (2024)
- 页面: 43-47
- 栏目: Pharmaceutical chemistry
- URL: https://journals.eco-vector.com/1560-9596/article/view/627115
- DOI: https://doi.org/10.29296/25877313-2024-02-05
- ID: 627115
如何引用文章
详细
Introduction. Alzheimer's disease is one of the most common forms of dementia, the pathogenesis of which is based on the accumulation of β–amyloid plaques in brain structures and the development of cholinergic deficiency.
The aim of the study was to evaluate the effect of chalcone analogues on the change in acetylcholinesterase activity and the process of β-amyloid aggregation in vitro.
Material and methods. The tested compounds were six bis-substituted chalcone analogues, which were dissolved in dimethylsulfoxide during the analysis to obtain double dilutions. The effect of the studied substances on the activity of acetylcholinesterase was evaluated by the modified Ellman method. The change in the aggregation process of β-amyloid particles was determined in reaction with congo red after 3, 6 and 9 days of incubation. Based on the obtained results of the «% inhibition- concentration» relationships, the IC50 index was calculated, which was expressed in mmol/ml.
Results. In the course of the study, it was shown that the analyzed chalcone analogues inhibit the aggregation of β-amyloid particles starting from the 6th day of incubation with a maximum on the 9th day. At the same time, the compounds that showed the highest level of activity were trimethoxy-substituted substances under the codes AZBAX4 and AZBAX6, whose IC50 on the 9th day of the study was 21.4±0.928 mmol/ml and 32.4±0.456 mmol/ml, respectively. Also, a high level of anticholinesterase properties was established for these compounds with IC50 of 35.9±0.991mmol/ml and 25.1±0.261 mmol/ml, respectively. The rest of the tested compounds showed a lower level of activity.
Conclusion. The study showed that chalcone analogues under the codes AZBAX4 and AZBAX6 inhibit the activity of acetylcholinesterase and the process of aggregation of β-amyloid in vitro, which makes these compounds promising for further study in order to develop medicines for the pathogenetic treatment of Alzheimer's disease.
全文:
作者简介
D. Pozdnyakov
Pyatigorsk Medical and Pharmaceutical Institute
编辑信件的主要联系方式.
Email: pozdniackow.dmitry@yandex.ru
Ph.D. (Pharm.), Associate Professor, Head of the Department of Pharmacology with Clinical Pharmacology Course
俄罗斯联邦, PyatigorskA. Vikhor
Pyatigorsk Medical and Pharmaceutical Institute
Email: nastyavihori@gmail.com
Student
俄罗斯联邦, PyatigorskV. Rukovitsina
Pyatigorsk Medical and Pharmaceutical Institute
Email: rukovitcinavika@mail.ru
Ph.D. (Pharm.), Senior Lecturer, Department of Organic Chemistry
俄罗斯联邦, PyatigorskE. Oganesyan
Pyatigorsk Medical and Pharmaceutical Institute
Email: pozdniackow.dmitry@yandex.ru
Dr.Sc. (Pharm.), Professor, Head of the Department of Organic Chemistry
俄罗斯联邦, PyatigorskA. Pleten
Moscow State Medical and Dental University named after A.I. Evdokimov of the Ministry of Health of the Russia
Email: pozdniackow.dmitry@yandex.ru
Dr.Sc. (Biol.), Professor of the Department of Biological Chemistry
俄罗斯联邦, MoscowA. Prokopov
Moscow State Medical and Dental University named after A.I. Evdokimov of the Ministry of Health of the Russia
Email: pozdniackow.dmitry@yandex.ru
Dr.Sc. (Chem.), Associate Professor, Head of Department of General and Bioorganic Chemistry
俄罗斯联邦, MoscowT. Tatarenko-Kozmina
Moscow State Medical and Dental University named after A.I. Evdokimov of the Ministry of Health of the Russia
Email: pozdniackow.dmitry@yandex.ru
Dr.Sc. (Biol.), Professor, Head of Department of Medical Biology with the Fundamentals of Cellular and Molecular Biotechnology
俄罗斯联邦, Moscow参考
- Khan S., Barve K.H., Kumar M.S. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. Curr Neuropharmacol. 2020; 18(11): 1106‒1125. doi: 10.2174/1570159X18666200528142429.
- Barage S.H., Sonawane K.D. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015; 52: 1‒18. doi: 10.1016/j.npep.2015.06.008.
- Brum W.S., de Bastiani M.A., Bieger A., et al. A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimers Dement (N Y). 2022; 8(1): e12270. Pub-lished 2022 Mar 13. doi: 10.1002/trc2.12270.
- Hampel H., Mesulam M.M., Cuello A.C., et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018; 141(7): 1917‒1933. doi: 10.1093/brain/awy132.
- Podtelezhnikov A.A., Tanis K.Q., Nebozhyn M., et al. Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging. PLoS One. 2011; 6(12): e29610. doi: 10.1371/journal.pone.0029610.
- Ferreira-Vieira T.H., Guimaraes IM, Silva F.R., Ribeiro F.M. Alzheimer's disease: Targeting the Cholinergic System. Curr Neuropharmacol. 2016; 14(1): 101‒115. doi: 10.2174/1570159x13666150716165726.
- Yu T.W., Lane H.Y., Lin C.H. Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. Int J Mol Sci. 2021 Jul 30; 22(15): 8208. doi: 10.3390/ijms22158208. PMID: 34360973; PMCID: PMC8348485.
- Wang W., Zhao C., Zhu D., Gong G., Du W. Inhibition of amyloid peptide fibril formation by gold-sulfur complexes. J InorgBiochem. 2017; 171: 1‒9. doi: 10.1016/j.jinorgbio.2017.02.021.
- Durmaz Ş., Evren A.E., Sağlık B.N., et al. Synthesis, anticholinesterase activity, molecular docking, and molecular dynamic simulation studies of 1,3,4-oxadiazole derivatives. Arch Pharm (Weinheim). 2022; 355(11): e2200294. doi: 10.1002/ardp.202200294.
- Thapa A., Jett S.D., Chi E.Y. Curcumin Attenuates Amyloid-β Aggregate Toxicity and Modulates Amyloid-β Aggregation Pathway. ACS Chem Neurosci. 2016; 7(1): 56‒68. doi: 10.1021/acschemneuro.5b00214.
- Tello-Franco V., Lozada-García M.C., Soriano-García M. Experimental and computational studies on the inhibition of acetylcholinesterase by curcumin and some of its derivatives. Curr Comput Aided Drug Des. 2013; 9(2): 289‒298. doi: 10.2174/15734099113099990007.